Anti-Insulin Receptor pY1361 (RABBIT) Antibody

Referência 600-401-MR0S

Tamanho : 25ul

Marca : Rockland Immunochemicals

Solicitar mais informações

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Specifications for Insulin Receptor phospho Y1361 Antibody

Product Details

Anti-Insulin Receptor pY1361 (RABBIT) Antibody - 600-401-MR0
Insulin Receptor, EC 2.7.10.1, IR, CD220 Antigen, HHF5, Rabbit anti-Insulin receptor, INSR
Rabbit
Polyclonal
IgG

Target Details

INSR  - View All INSR Products
Human
Phosphorylation
Conjugated Peptide
Anti-Insulin Receptor pY1361 antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to the C-Terminal portion near the phosphorylation Y1361 of the human Insulin Receptor conjugated to Keyhole Limpet Hemocyanin (KLH).
This affinity purified antibody is directed against human Insulin Receptor.  Rabbit Anti-Insulin Receptor pY1361 Antibody was prepared from monospecific antiserum by delipidation and defibrination, affinity purification, followed by cross adsorption. This phospho specific polyclonal antibody is specific for pY1361 human Insulin Receptor. Reactivity with non-phosphorylated Y1361 is minimal.  A BLAST analysis was used to suggest cross-reactivity with the antigen based on 100% homology with the immunizing sequence to human, rat, mouse, and xenopus laevis.
P06213 - UniProtKB
NP_000199.2 - NCBI Protein
3643 - Gene ID

Application Details

Dot Blot, ELISA, WB
Anti-Insulin Receptor pY1361 Antibody has been tested in ELISA, Dot Blot, and Western Blot. This antibody may be suitable for Immunofluorescence and Immunohistochemistry. Expect ~156kDa in appropriate tissues or lysates on western blots.

Formulation

1.0 mg/ml by UV absorbance at 280 nm
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
0.01% (w/v) Sodium Azide
None

Shipping & Handling

Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.

Background

Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Anti-Insulin Receptor pY1361 Antibody is useful for researchers interested in Donohue Syndrome, Insulin-Resistant Diabetes Mellitus, RET signaling, AMP-activated Protein Kinase (AMPK) Signaling Pathways, and protein tyrosine kinase activity.

Related Protocols

Adherent Cell Lysis Protocol
ELISA Protocol
Fluorescent Western Blotting Protocol
General Immunoblotting Protocol
Histone Immunoblotting Protocol
In-Cell Western (ICW) Protocol
IP-WB with TrueBlot® Protocol
Multi-Lysate Western Blotting Protocol
Nuclear & Cytoplasmic Extract Protocol
Sandwich ELISA Protocol for Collagen
Suspension Cultured Cell Lysis Protocol
Western Blotting (WB) Protocol

Certificate of Analysis Lookup

Invalid lot number

Search

If you need help finding your CoA, contact us

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.

Related Resources